1. Home
  2. SLDP vs ZYME Comparison

SLDP vs ZYME Comparison

Compare SLDP & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLDP
  • ZYME
  • Stock Information
  • Founded
  • SLDP 2011
  • ZYME 2003
  • Country
  • SLDP United States
  • ZYME United States
  • Employees
  • SLDP N/A
  • ZYME N/A
  • Industry
  • SLDP Electrical Products
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLDP Energy
  • ZYME Health Care
  • Exchange
  • SLDP Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • SLDP 1.3B
  • ZYME 1.2B
  • IPO Year
  • SLDP N/A
  • ZYME 2017
  • Fundamental
  • Price
  • SLDP $6.61
  • ZYME $19.40
  • Analyst Decision
  • SLDP Strong Buy
  • ZYME Strong Buy
  • Analyst Count
  • SLDP 1
  • ZYME 7
  • Target Price
  • SLDP $7.00
  • ZYME $22.00
  • AVG Volume (30 Days)
  • SLDP 17.0M
  • ZYME 1.1M
  • Earning Date
  • SLDP 11-04-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • SLDP N/A
  • ZYME N/A
  • EPS Growth
  • SLDP N/A
  • ZYME N/A
  • EPS
  • SLDP N/A
  • ZYME N/A
  • Revenue
  • SLDP $19,802,000.00
  • ZYME $134,481,000.00
  • Revenue This Year
  • SLDP $27.38
  • ZYME $99.52
  • Revenue Next Year
  • SLDP $37.97
  • ZYME N/A
  • P/E Ratio
  • SLDP N/A
  • ZYME N/A
  • Revenue Growth
  • SLDP 9.85
  • ZYME 116.21
  • 52 Week Low
  • SLDP $0.68
  • ZYME $9.03
  • 52 Week High
  • SLDP $8.86
  • ZYME $20.17
  • Technical
  • Relative Strength Index (RSI)
  • SLDP 53.53
  • ZYME 59.94
  • Support Level
  • SLDP $6.17
  • ZYME $16.00
  • Resistance Level
  • SLDP $8.02
  • ZYME $19.98
  • Average True Range (ATR)
  • SLDP 0.85
  • ZYME 0.93
  • MACD
  • SLDP 0.02
  • ZYME -0.03
  • Stochastic Oscillator
  • SLDP 40.05
  • ZYME 81.64

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: